IBI-324

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameIBI-324
Drug Alias NameIBI-324OLN324
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionVascular endothelial growth factor A inhibitorsAngiopoietin-2 inhibitors
TargetsVascular endothelial growth factor AAngiopoietin-2
Therapy Area/IndicationsDiabetic macular oedemaMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto RicoMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesInnovent Biologics (Usa), Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesOllin Biosciences IncInnovent Biologics(Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A